Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.
Stanford is currently accepting patients for this trial.
Intervention(s):
- behavioral: Brief Behavioral Therapy
- behavioral: Telephone-Based Intervention
- other: Educational Intervention
- behavioral: Telephone-Based Intervention
Eligibility
Inclusion Criteria:
- Newly diagnosed breast cancer (stage I, II, III)
- Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least
6 weeks of chemotherapy treatment remaining; patients are eligible any time before
chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle;
(Note: use of biologics [e.g., Herceptin (trastuzumab)] is permitted)
- For patients on a weekly regimen, there should be at least 3 dosages of
chemotherapy remaining
- For patients on either a 2 week or 3 week cycle, there should be at least 2
dosages of chemotherapy remaining
- Patients will not be dropped from the study if their chemotherapy is discontinued
after they are enrolled
- Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia
Severity Index
- (Note: this measure will be repeated again at baseline assessment)
- Report sleep problems that began or got worse with the diagnosis of cancer or with
chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer
or with chemotherapy?)
- Be able to speak and read English
- Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use
sleep aids as needed; patients taking sleep aids every night are excluded; use of
melatonin every night is permitted and these patients are not excluded
- Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are
scheduled to wear it
Exclusion Criteria:
- Have diagnosis of breast cancer stage IV
- Have sleep problems that began before diagnosis and have not changed since diagnosis
- Self-report or have a medical record of an unstable comorbid medical or psychiatric
condition that would make it unsafe or impossible to adhere to the study protocol
- Have a clinical diagnosis of sleep apnea or restless leg syndrome
- Be unable or unwilling to discontinue anxiolytic medication within 4 hours of
intervention sessions
- Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is
permitted
- Patients who are shift workers are excluded; shift worker is defined as someone who
has irregular work and sleep hours (such as working a non-traditional schedule: e.g.,
4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night
shifts, or starting work between 4am and 7am)
- Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left
ventricular assist device, etc.)
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Oxana Palesh
650-725-7011
I'm interested
Psoriasis Clinical Trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.
Stanford is currently accepting patients for this trial.
Intervention(s):
- behavioral: Brief Behavioral Therapy
- behavioral: Telephone-Based Intervention
- other: Educational Intervention
- behavioral: Telephone-Based Intervention
Eligibility
Inclusion Criteria:
- Newly diagnosed breast cancer (stage I, II, III)
- Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least
6 weeks of chemotherapy treatment remaining; patients are eligible any time before
chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle;
(Note: use of biologics [e.g., Herceptin (trastuzumab)] is permitted)
- For patients on a weekly regimen, there should be at least 3 dosages of
chemotherapy remaining
- For patients on either a 2 week or 3 week cycle, there should be at least 2
dosages of chemotherapy remaining
- Patients will not be dropped from the study if their chemotherapy is discontinued
after they are enrolled
- Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia
Severity Index
- (Note: this measure will be repeated again at baseline assessment)
- Report sleep problems that began or got worse with the diagnosis of cancer or with
chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer
or with chemotherapy?)
- Be able to speak and read English
- Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use
sleep aids as needed; patients taking sleep aids every night are excluded; use of
melatonin every night is permitted and these patients are not excluded
- Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are
scheduled to wear it
Exclusion Criteria:
- Have diagnosis of breast cancer stage IV
- Have sleep problems that began before diagnosis and have not changed since diagnosis
- Self-report or have a medical record of an unstable comorbid medical or psychiatric
condition that would make it unsafe or impossible to adhere to the study protocol
- Have a clinical diagnosis of sleep apnea or restless leg syndrome
- Be unable or unwilling to discontinue anxiolytic medication within 4 hours of
intervention sessions
- Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is
permitted
- Patients who are shift workers are excluded; shift worker is defined as someone who
has irregular work and sleep hours (such as working a non-traditional schedule: e.g.,
4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night
shifts, or starting work between 4am and 7am)
- Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left
ventricular assist device, etc.)
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Oxana Palesh
650-725-7011
I'm interested
Dermatology Clinical Trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.
Stanford is currently accepting patients for this trial.
Intervention(s):
- behavioral: Brief Behavioral Therapy
- behavioral: Telephone-Based Intervention
- other: Educational Intervention
- behavioral: Telephone-Based Intervention
Eligibility
Inclusion Criteria:
- Newly diagnosed breast cancer (stage I, II, III)
- Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least
6 weeks of chemotherapy treatment remaining; patients are eligible any time before
chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle;
(Note: use of biologics [e.g., Herceptin (trastuzumab)] is permitted)
- For patients on a weekly regimen, there should be at least 3 dosages of
chemotherapy remaining
- For patients on either a 2 week or 3 week cycle, there should be at least 2
dosages of chemotherapy remaining
- Patients will not be dropped from the study if their chemotherapy is discontinued
after they are enrolled
- Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia
Severity Index
- (Note: this measure will be repeated again at baseline assessment)
- Report sleep problems that began or got worse with the diagnosis of cancer or with
chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer
or with chemotherapy?)
- Be able to speak and read English
- Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use
sleep aids as needed; patients taking sleep aids every night are excluded; use of
melatonin every night is permitted and these patients are not excluded
- Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are
scheduled to wear it
Exclusion Criteria:
- Have diagnosis of breast cancer stage IV
- Have sleep problems that began before diagnosis and have not changed since diagnosis
- Self-report or have a medical record of an unstable comorbid medical or psychiatric
condition that would make it unsafe or impossible to adhere to the study protocol
- Have a clinical diagnosis of sleep apnea or restless leg syndrome
- Be unable or unwilling to discontinue anxiolytic medication within 4 hours of
intervention sessions
- Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is
permitted
- Patients who are shift workers are excluded; shift worker is defined as someone who
has irregular work and sleep hours (such as working a non-traditional schedule: e.g.,
4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night
shifts, or starting work between 4am and 7am)
- Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left
ventricular assist device, etc.)
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Oxana Palesh
650-725-7011
I'm interested
Pediatric Dermatology Clinical Trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.
Stanford is currently accepting patients for this trial.
Intervention(s):
- behavioral: Brief Behavioral Therapy
- behavioral: Telephone-Based Intervention
- other: Educational Intervention
- behavioral: Telephone-Based Intervention
Eligibility
Inclusion Criteria:
- Newly diagnosed breast cancer (stage I, II, III)
- Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least
6 weeks of chemotherapy treatment remaining; patients are eligible any time before
chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle;
(Note: use of biologics [e.g., Herceptin (trastuzumab)] is permitted)
- For patients on a weekly regimen, there should be at least 3 dosages of
chemotherapy remaining
- For patients on either a 2 week or 3 week cycle, there should be at least 2
dosages of chemotherapy remaining
- Patients will not be dropped from the study if their chemotherapy is discontinued
after they are enrolled
- Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia
Severity Index
- (Note: this measure will be repeated again at baseline assessment)
- Report sleep problems that began or got worse with the diagnosis of cancer or with
chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer
or with chemotherapy?)
- Be able to speak and read English
- Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use
sleep aids as needed; patients taking sleep aids every night are excluded; use of
melatonin every night is permitted and these patients are not excluded
- Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are
scheduled to wear it
Exclusion Criteria:
- Have diagnosis of breast cancer stage IV
- Have sleep problems that began before diagnosis and have not changed since diagnosis
- Self-report or have a medical record of an unstable comorbid medical or psychiatric
condition that would make it unsafe or impossible to adhere to the study protocol
- Have a clinical diagnosis of sleep apnea or restless leg syndrome
- Be unable or unwilling to discontinue anxiolytic medication within 4 hours of
intervention sessions
- Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is
permitted
- Patients who are shift workers are excluded; shift worker is defined as someone who
has irregular work and sleep hours (such as working a non-traditional schedule: e.g.,
4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night
shifts, or starting work between 4am and 7am)
- Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left
ventricular assist device, etc.)
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Oxana Palesh
650-725-7011
I'm interested
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.
Stanford is currently accepting patients for this trial.
Intervention(s):
- behavioral: Brief Behavioral Therapy
- behavioral: Telephone-Based Intervention
- other: Educational Intervention
- behavioral: Telephone-Based Intervention
Eligibility
Inclusion Criteria:
- Newly diagnosed breast cancer (stage I, II, III)
- Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least
6 weeks of chemotherapy treatment remaining; patients are eligible any time before
chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle;
(Note: use of biologics [e.g., Herceptin (trastuzumab)] is permitted)
- For patients on a weekly regimen, there should be at least 3 dosages of
chemotherapy remaining
- For patients on either a 2 week or 3 week cycle, there should be at least 2
dosages of chemotherapy remaining
- Patients will not be dropped from the study if their chemotherapy is discontinued
after they are enrolled
- Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia
Severity Index
- (Note: this measure will be repeated again at baseline assessment)
- Report sleep problems that began or got worse with the diagnosis of cancer or with
chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer
or with chemotherapy?)
- Be able to speak and read English
- Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use
sleep aids as needed; patients taking sleep aids every night are excluded; use of
melatonin every night is permitted and these patients are not excluded
- Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are
scheduled to wear it
Exclusion Criteria:
- Have diagnosis of breast cancer stage IV
- Have sleep problems that began before diagnosis and have not changed since diagnosis
- Self-report or have a medical record of an unstable comorbid medical or psychiatric
condition that would make it unsafe or impossible to adhere to the study protocol
- Have a clinical diagnosis of sleep apnea or restless leg syndrome
- Be unable or unwilling to discontinue anxiolytic medication within 4 hours of
intervention sessions
- Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is
permitted
- Patients who are shift workers are excluded; shift worker is defined as someone who
has irregular work and sleep hours (such as working a non-traditional schedule: e.g.,
4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night
shifts, or starting work between 4am and 7am)
- Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left
ventricular assist device, etc.)
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Oxana Palesh
650-725-7011
I'm interested
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.
Stanford is currently accepting patients for this trial.
Intervention(s):
- behavioral: Brief Behavioral Therapy
- behavioral: Telephone-Based Intervention
- other: Educational Intervention
- behavioral: Telephone-Based Intervention
Eligibility
Inclusion Criteria:
- Newly diagnosed breast cancer (stage I, II, III)
- Be receiving chemotherapy in either weekly, 2-week or 3-week cycles and have at least
6 weeks of chemotherapy treatment remaining; patients are eligible any time before
chemotherapy cycle 3 if on a 2- or 3-week cycle, or cycle 4 if on a 1-week cycle;
(Note: use of biologics [e.g., Herceptin (trastuzumab)] is permitted)
- For patients on a weekly regimen, there should be at least 3 dosages of
chemotherapy remaining
- For patients on either a 2 week or 3 week cycle, there should be at least 2
dosages of chemotherapy remaining
- Patients will not be dropped from the study if their chemotherapy is discontinued
after they are enrolled
- Report sleep disturbance of 8 (sum total of all 7 items) or greater on the Insomnia
Severity Index
- (Note: this measure will be repeated again at baseline assessment)
- Report sleep problems that began or got worse with the diagnosis of cancer or with
chemotherapy; (did your sleep problems begin or get worse with the diagnosis of cancer
or with chemotherapy?)
- Be able to speak and read English
- Patients can take sleep aids (e.g., hypnotics and sedatives) for insomnia if they use
sleep aids as needed; patients taking sleep aids every night are excluded; use of
melatonin every night is permitted and these patients are not excluded
- Be able and willing to wear an Actiwatch for the entire 24 hours of each day they are
scheduled to wear it
Exclusion Criteria:
- Have diagnosis of breast cancer stage IV
- Have sleep problems that began before diagnosis and have not changed since diagnosis
- Self-report or have a medical record of an unstable comorbid medical or psychiatric
condition that would make it unsafe or impossible to adhere to the study protocol
- Have a clinical diagnosis of sleep apnea or restless leg syndrome
- Be unable or unwilling to discontinue anxiolytic medication within 4 hours of
intervention sessions
- Take medication for sleep (e.g., hypnotics and sedatives) every night; melatonin is
permitted
- Patients who are shift workers are excluded; shift worker is defined as someone who
has irregular work and sleep hours (such as working a non-traditional schedule: e.g.,
4pm-midnight or 10pm-6am; a rotating schedule e.g., alternating between day and night
shifts, or starting work between 4am and 7am)
- Have an implanted device for heart failure (e.g., pacemaker, defibrillator, left
ventricular assist device, etc.)
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Oxana Palesh
650-725-7011
I'm interested